Startseite Bortezomib at therapeutic doses poorly passes the blood-brain barrier and does not impair cognition.
|

Bortezomib at therapeutic doses poorly passes the blood-brain barrier and does not impair cognition.

Seite drucken
Seite teilen
DRFZ NewsFlash abonnieren